Clinical Trial Update: A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation [Phase 2]

View source ↗

Summary

Phase 2 study of selpercatinib (Retevmo) in adults with advanced RET-altered solid tumors, including RET fusion–positive cancers and medullary thyroid carcinoma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Medullary Thyroid Carcinoma
• Ret Fusion-positive Solid Tumors
• Solid Tumor
• Tumors with Ret Activation

Drugs mentioned

• RETEVMO (selpercatinib)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Solid Tumor, Medullary Thyroid Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2022-06-02